C-MER Eye Care Holdings Limited (HK:3309)
:3309
Want to see HK:3309 full AI Analyst Report?
3309 Stock Chart & Stats
HK$1.70
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.70
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.11 - HK$2.16
Previous CloseN/A
Volume360.00K
Average Volume (3M)495.46K
Market Cap
HK$1.39B
Enterprise ValueHK$1.42B
Total Cash (Recent Filing)HK$465.96M
Total Debt (Recent Filing)HK$426.78M
Price to Earnings (P/E)20.7
Beta1.10
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.2%
Share Statistics
EPS (TTM)0.08
Shares Outstanding1,232,342,900
10 Day Avg. Volume419,185
30 Day Avg. Volume495,465
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.17
Price to Sales (P/S)1.07
P/FCF Ratio9.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent positive operating cash flow and strong free cash flow across 2022–2025 provide durable internal funding for capex, clinic upkeep and network expansion. The meaningful FCF step-up in 2025 strengthens liquidity, reduces near-term refinancing need and supports multi-month strategic investments.
Balance Sheet StrengthModerate, manageable leverage (debt-to-equity ~0.19–0.35), steady-to-up total assets and rising equity give the company financial flexibility. This balance-sheet profile helps absorb patient-volume cycles, supports measured M&A or capex, and reduces reliance on high-cost external financing over months.
Revenue Growth And Margin RecoveryMaterial revenue expansion in key years and a recovery to positive net income in 2025, with healthy gross and EBITDA margins, indicate scalable unit economics in the core ophthalmic business. Sustained operating margins improve resiliency of cash flow and support multi-month planning for service capacity and pricing strategies.
Bears Say
Earnings VolatilityRecurring swings to losses in 2022 and 2024 create material uncertainty about sustainable profitability. Such volatility undermines predictable earnings and complicates medium-term budgeting, capital allocation and confidence in management's ability to deliver steady operating performance over the next 2–6 months.
Inconsistent Shareholder ReturnsReturns to shareholders have been uneven, with negative years interspersed with modest positives. This inconsistency suggests difficulty converting operational improvements into sustained ROE and may constrain investor confidence, dividend policy clarity and access to lower-cost capital in the medium term.
FCF Volatility And Reporting GapsWhile absolute free cash flow is strong, year-to-year volatility and missing coverage/conversion metrics (0.0 values in 2025) limit confidence in repeatable cash conversion rates. This complicates longer-term budgeting for capex, working capital and expansion plans and raises execution risk.
C-MER Eye Care Holdings Limited News
3309 FAQ
What was C-MER Eye Care Holdings Limited’s price range in the past 12 months?
C-MER Eye Care Holdings Limited lowest stock price was HK$1.11 and its highest was HK$2.16 in the past 12 months.
What is C-MER Eye Care Holdings Limited’s market cap?
C-MER Eye Care Holdings Limited’s market cap is HK$1.39B.
When is C-MER Eye Care Holdings Limited’s upcoming earnings report date?
C-MER Eye Care Holdings Limited’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.
How were C-MER Eye Care Holdings Limited’s earnings last quarter?
C-MER Eye Care Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.042 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.042.
Is C-MER Eye Care Holdings Limited overvalued?
According to Wall Street analysts C-MER Eye Care Holdings Limited’s price is currently Overvalued.
Does C-MER Eye Care Holdings Limited pay dividends?
C-MER Eye Care Holdings Limited pays a Annually dividend of HK$0.02 which represents an annual dividend yield of 1.2%. See more information on C-MER Eye Care Holdings Limited dividends here
What is C-MER Eye Care Holdings Limited’s EPS estimate?
C-MER Eye Care Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does C-MER Eye Care Holdings Limited have?
C-MER Eye Care Holdings Limited has 1,232,342,900 shares outstanding.
What happened to C-MER Eye Care Holdings Limited’s price movement after its last earnings report?
C-MER Eye Care Holdings Limited reported an EPS of HK$0.042 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.6%.
Which hedge fund is a major shareholder of C-MER Eye Care Holdings Limited?
Currently, no hedge funds are holding shares in HK:3309
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C-MER Eye Care Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.66%
12-Months-Change
Fundamentals
Return on Equity
5.64%
Trailing 12-Months
Asset Growth
0.46%
Trailing 12-Months
Company Description
C-MER Eye Care Holdings Limited
C-MER Eye Care Holdings Ltd. engages in the provision of treatments and therapy services for ophthalmic diseases. It operates through the Provision of Ophthalmic Services and the Sale of Vision Aid Products segments. The company was founded by Shun Chiu Lam on February 1, 2016 and is headquartered in Hong Kong.
Technical Analysis
Options Prices
Currently, No data available
---